title: Radioiodine therapy of metastatic lesions of differentiated thyroid cancer.
abstract: Seventy years after the first successful radioiodine treatment of metastatic differentiated thyroid cancer (DTC), radioiodine (131I) therapy for this type of tumor is still without alternative. During the last decade, some key issues such as individual dosimetry, and preparation of 131I therapy by recombinant human TSH have been addressed, but this has not yet lead to conclusive results; furthermore a number of questions related to indication, preparation, and treatment protocol of 131I therapy still remain unanswered. In this review, we will address the literature pertaining to the latest developments in the field of 131I therapy of advanced DTC and we will give an overview of the state of the art regarding patient preparation, dosimetry, and therapy.
authors.affiliation: Department of Nuclear Medicine, University of Ulm, Albert-Einstein-Allee 23, Ulm, Germany. markus.luster@uniklinik-ulm.de
authors.forename: M
authors.initials: M
authors.lastname: Luster
authors.forename: H
authors.initials: H
authors.lastname: Hänscheid
authors.forename: L S
authors.initials: LS
authors.lastname: Freudenberg
authors.forename: F A
authors.initials: FA
authors.lastname: Verburg
mesh_terms: D018265:Carcinoma, Papillary, Follicular / Q000532:radiotherapy* / Q000556:secondary; D002454:Cell Differentiation; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D009362:Neoplasm Metastasis; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D013964:Thyroid Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D057073:Thyrotropin Alfa / Q000627:therapeutic use
chemical_list: D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D057073:Thyrotropin Alfa